메뉴 건너뛰기




Volumn 3, Issue 3, 2006, Pages 114-115

Chemotherapy-induced neutropenia: A useful predictor of treatment efficacy?

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; EPIRUBICIN; GROWTH FACTOR;

EID: 33645338435     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0445     Document Type: Review
Times cited : (9)

References (10)
  • 1
    • 0029743058 scopus 로고    scopus 로고
    • Dose calculation of anticancer drugs: A review of the current practice and introduction of an alternative
    • Gurney H (1996) Dose calculation of anticancer drugs: A review of the current practice and introduction of an alternative. J Clin Oncol 14: 2590-2611
    • (1996) J Clin Oncol , vol.14 , pp. 2590-2611
    • Gurney, H.1
  • 2
    • 0037156937 scopus 로고    scopus 로고
    • How to calculate the dose of chemotherapy
    • Gurney H (2002) How to calculate the dose of chemotherapy. Br J Cancer 86: 1297-1302
    • (2002) Br J Cancer , vol.86 , pp. 1297-1302
    • Gurney, H.1
  • 3
    • 24044554232 scopus 로고    scopus 로고
    • I don't underdose my patients...do I?
    • Gurney H (2005) I don't underdose my patients...do I? Lancet Oncol 6: 637-638
    • (2005) Lancet Oncol , vol.6 , pp. 637-638
    • Gurney, H.1
  • 4
    • 0031031616 scopus 로고    scopus 로고
    • Haematological toxicity: A marker of adjuvant chemotherapy efficacy in stage II and III breast cancer
    • Saarto T et al. (1997) Haematological toxicity: A marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer 75: 301-305
    • (1997) Br J Cancer , vol.75 , pp. 301-305
    • Saarto, T.1
  • 5
    • 0035875895 scopus 로고    scopus 로고
    • Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma
    • Mayers C et al. (2001) Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer 91: 2246-2257
    • (2001) Cancer , vol.91 , pp. 2246-2257
    • Mayers, C.1
  • 6
    • 0348013443 scopus 로고    scopus 로고
    • Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer
    • Cameron DA et al. (2003) Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. Br J Cancer 89: 1837-1842
    • (2003) Br J Cancer , vol.89 , pp. 1837-1842
    • Cameron, D.A.1
  • 7
    • 24044542973 scopus 로고    scopus 로고
    • Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: A pooled analysis of three randomised trials
    • Di Maio M et al. (2005) Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: A pooled analysis of three randomised trials. Lancet Oncol 6: 669-677
    • (2005) Lancet Oncol , vol.6 , pp. 669-677
    • Di Maio, M.1
  • 8
    • 0032788580 scopus 로고    scopus 로고
    • The leucocyte nadir, a predictor of chemotherapy efficacy?
    • Kvinnsland S (1999) The leucocyte nadir, a predictor of chemotherapy efficacy? Br J Cancer 80: 1681
    • (1999) Br J Cancer , vol.80 , pp. 1681
    • Kvinnsland, S.1
  • 9
    • 7144253806 scopus 로고    scopus 로고
    • Dosage of adjuvant G-CSF (filgrastim)-supported FEC polychemotherapy based on equivalent haematological toxicity in high-risk breast cancer patients
    • Scandinavian Breast Group, Study SBG 9401
    • Bergh J et al. (1998) Dosage of adjuvant G-CSF (filgrastim)-supported FEC polychemotherapy based on equivalent haematological toxicity in high-risk breast cancer patients. Scandinavian Breast Group, Study SBG 9401. Ann Oncol 9: 403-411
    • (1998) Ann Oncol , vol.9 , pp. 403-411
    • Bergh, J.1
  • 10
    • 0034699950 scopus 로고    scopus 로고
    • Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: A randomised trial. Scandinavian Breast Group 9401 study
    • Bergh J et al. (2000) Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: A randomised trial. Scandinavian Breast Group 9401 study. Lancet 356: 1384-1391
    • (2000) Lancet , vol.356 , pp. 1384-1391
    • Bergh, J.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.